

Article

Not peer-reviewed version

Disruption of SARS-CoV-2 Virus Replication in the Presence of Potassium Ribosate

[María Gabriela Sánchez-Vega](#)*, [Eliseo Garuti Valsé Pantellini](#), [Santiago Melon García](#), [José Antonio Boga](#), [Zulema Perez-Martinez](#), [Guido Paoli](#), [Covadonga González Lazcano](#), [Marta Elena Alvarez-Argüelles](#), [Susana Rojo Alba](#), [Cristina Ochoa-Varela](#)

Posted Date: 5 February 2025

doi: 10.20944/preprints202502.0268.v1

Keywords: SARS-CoV-2; potassium; ribose; immune response



Preprints.org is a free multidisciplinary platform providing preprint service that is dedicated to making early versions of research outputs permanently available and citable. Preprints posted at Preprints.org appear in Web of Science, Crossref, Google Scholar, Scilit, Europe PMC.

Copyright: This open access article is published under a Creative Commons CC BY 4.0 license, which permit the free download, distribution, and reuse, provided that the author and preprint are cited in any reuse.

Article

Disruption of SARS-CoV-2 Virus Replication in the Presence of Potassium Ribosate

María G. Sánchez-Vega ¹, Zulema Pérez Martínez ², José Boga Riveiro ², Guido Paoli ³, Covadonga Gonzalez Lazcano ¹, Cristina Varela Ochoa ², Susana Rojo Alba ², Marta E. Alvarez-Argüelles ² and Santiago Melón García ² and Eliseo Garuti Valsé Pantellini ¹

¹ Virology Section of the Microbiology Laboratory Services of the Hospital Universitario Central de Asturias, Oviedo, Asturias, Spain

² Biochemical Research A.E.I.E. Noreña, Asturias, Spain

³ Valsé Pantellini Foundation

* Correspondence: Biochemical Research A.E.I.E. Barreda Polygon, Streep Solellero, N°2, 33180 Noreña, Asturias, Spain. Phone: 34- 984108338 / 34-664665487; idibiochemicalresearchaeie@gmail.com

Abstract: The Potassium Ribosate, which has been shown to have an enhancer effect in limiting replication and viability in cancer cells, also appears to show promise in altering viral replication. To determine its activity against SARS-CoV-2, an inhibition assay was performed using 26 strains obtained from clinical samples from patients isolated on the Vero E6 cell line. For this, the strains were serially diluted and treated with 125mM Potassium Ribosate. The Potassium Ribosate was administered at a single concentration (125mM stock) in two ways: 24 hours before infection and in the culture medium after removal of the infectious inoculum. The culture medium was changed 3 days after inoculation. Seven days after inoculation, a visual reading of the cytopathic effect (ECP) and RT-qRCP were performed to calculate the viral load. Reduction of 3log (9Ct) between with or without Ribosate was considered a very good response. Of the 26 evaluable strains, a reduction in viral replication was observed in 13 (50%) and 16 (61.5%) of the pre-treatment and treatment study (p=0.29). This response was good or very good in 10 (38.4%) and 11 (42.3%) (p=0.4), respectively. Potassium Ribosate administration reduced the viral load of SARS-CoV-2 cultures in Vero E6 cells in more than half of the cases, both at infection and pre-infection administration.

Keywords: SARS-CoV-2; potassium; ribose; immune response

One of the current challenges in SARS-CoV-2 infection is finding reagents/drugs/products that control viral replication directly (antivirals) or indirectly (immunomodulators).

Numerous reviews of SARS-CoV-2 have been conducted in the scientific literature. [1a,b,c] All this knowledge is of relevance to the identification and understanding of this disease in the face of the different treatments that may continue to emerge. This background evidence shows that the immune response and possible early evasion play a crucial role in decreasing the viral load or infectious dose that governs disease severity and transmission. [2a,b,c]

Potassium Ribosate (RK), is a compound that has been studied for several years by the Biochemical Research A.E.I.E., in collaboration with the Valsé Pantellini Foundation. These structures have been developing research projects based on Potassium salts, in particular Potassium Ascorbate and Potassium Ribosate, for several years on the basis of the studies of the Italian biochemist Gianfrancesco Valsé Pantellini in the second half of the last century and published between 1970 and 1999. [3–6]. The main objective of the above-mentioned projects was to assess the impact of these molecules to try to both prevent and combat degenerative pathologies, in particular oncological ones. Over the years, collaborations have been launched that have produced encouraging results both "in

vitro" [7–15] and "*in vivo*", [16–19] developing a rational rationale for the use of these molecules. [18] We know that potassium is a very important metabolic regulator, [20–22] but its particular characteristic of stabilising telomeres through the so-called G-quadruplexes seems less well known. [11–14,23]

It is this last feature that has allowed to focus attention on viral issues, with special attention to SARS-CoV-2, assuming that Potassium may interfere with viral replication thanks to its action of maintenance and stabilisation of the genetic structure, inhibiting or limiting retrotranscription. [24a] The mechanism underlying this action is the physical process of resonance, within the biophysical paradigm of living systems. [24b] In this way, Potassium Ribosate could be used as a therapeutic method. It should be noted that preliminary tests in mice treated with RK showed no acute toxicity of the compound (Acute Toxicity Study, according to GLP regulations). [25]

Therefore, a study has been developed to assess the influence of RK on SARS-CoV-2. The Virology section of the Microbiology laboratory Services of the Hospital Universitario Central de Asturias (HUCA) and the Foundation for Biosanitary Research of Asturias in conjunction with Biochemical Research A.E.I.E. developed an *in vitro* viral growth inhibition assay to monitor whether the active ingredient RK increased the resistance or defence capacity of the cell against SARS-CoV-2 infection.

Material and Methods

Material

All assays were performed in the biosafety laboratory of the Virology Section of the HUCA under appropriate safety conditions.

In order to carry out the different inhibition assays and to quantify the effectiveness of aqueous Potassium Ribosate (Biochemical Research A.E.I.E., Spain) against the SARS-CoV-2 viral pathogen, a total of 29 strains were used, which were processed at three different times in the following way: 6 different strains in assay-1, 8 different strains in assay-2 and 15 strains, also different, in assay-3. These strains belonged to variant B.1.1.1.1.7 (α), all these strains were isolated from clinical samples in established Vero-E6 cell line, according to standardised protocols and stored in the viral section's biobank. Classification of the variants corresponding to each of the strains was performed either by allelic discrimination techniques or by sequencing, according to the protocol of the Section.

Methods

For the inhibition assays, the viral titre of each strain was determined before or at the same time as the assay, depending on the needs of the moment (as determined later).

Once the titre of each strain was determined, the inhibition study was carried out according to classical methods adapted in the laboratory. [26–29]

a) Strain titration

Strains of all SARS-CoV-2 viruses were titrated for 50% CI according to inoculation assays in 96-well plates with confluent cell substrate (Vero-E6 cells). For this, starting from a viral culture, decreasing dilutions of the virus were made in base 10 and 200 μ l of the inoculum was inoculated into the wells of the plate. They were then incubated at 37°C for 1 hour in a 5% CO₂ atmosphere. The inoculum was then removed and incubated for up to 7 days under the conditions described above.

Viral growth was determined by DBS, Neutral Red and/or PCR.

(a.1) Cytopathic Effect (CPE)

The Karber Method was performed by visualizing the cytopathic effect produced by the infection and calculating the IC 50% (Figure 1).




Figure 1. Images of cultures: (1) Uninfected Vero E6 cells; (2) CPE of titre -2 of a strain at 7 days; (3) CPE of titre -5 at 7 days.

(a.2) Vital Dye (Neutral Red)

To assess viral infection more accurately, the Neutral Red vital dye uptake method was sometimes applied: after 7 days of infection in the 96-well plate, 50µl of a buffered Neutral Red solution was added to each well. The plates were incubated for 45 minutes at 37°C and in a 5% CO₂ atmosphere. Subsequently, the medium was removed, and the wells were washed twice with PBS. Finally, 150µl of ethanol phosphate buffer was added to elute the vital dye incorporated by the viable cells. The absorbance was read at 550nm (reference value of 620nm) on a PR 4100 spectrophotometer.

(a.3) Genomic Detection and Quantification: Real-Time RT-PCR of SARS-Cov2

From each well, 50µl of supernatant was collected for subsequent viral quantification by genomic amplification (PCR, Figure 2). Viral replication in each of the cell culture dilutions was determined by averaging the viral load of all wells, by qPCR technique routinely used in the HUCA Virology Laboratory for virus diagnosis. [30,31] Briefly, once the viral genome was extracted with the Magnapure LC96 system (Roche Diagnostic, S.L., Switzerland), 5 µl was mixed with 10 µl of a reaction containing specific primers and MGB probes against the polymerase fragment and the N gene and with Fast-stepon 4x reagent (ThermoFisher, S.A. USA).

The results obtained were expressed as a function of the Ct (PCR cycles) observed (the higher the Ct the lower the viral load). A Ct of 40 is assumed to mean no viral growth.




Figure 2. Amplification of SARS-Cov2 in wells without Ribosate (red), with pre-treatment (violet) and without pre-treatment (green) in logarithmic (a) and linear (b) scale.

(b) Inhibition assay

In the trials carried out with different strains, two types of Potassium Ribosate administrations were performed: 24 hours prior to virus inoculation, which is referred pre-treatment; or immediately after pathogen inoculation, which is referred treatment.

At all times, the concentration at which Potassium Ribosate was administered was 125mM (Stock concentration as stated by Biochemical Research A.E.I.E., derived from in vitro assays). [14–22,32]

To infect the cells, the medium was removed and 200 µl of each of the serial dilutions were added and incubated at 37°C for 1 hour in a 5% CO₂ atmosphere. Subsequently, the inoculum was removed, and fresh maintenance medium was administered without and with RK. Three days after infection, the medium was renewed, and each culture was maintained under the same conditions as the original ones. In all cases, viral replication was measured at 7 days post-inoculation. These were performed by visualization of the cytopathic effect and by PCR quantification (molecular readout).

In the latter assay, analysis by Neutral Red staining was added in some cases. In order to assess the results obtained and quantify the degree of impact of Potassium Ribosate on viral replication of the different strains used in the assays, the following scale of criteria was developed:

(b.1) Biological Readout Response (DBS/Neutral Red):

- DBS: difference of more than 2 log between the titre with and without reagent.
- Neutral Red: less than 50% growth in the reading title.

(b.2) Molecular Readout Endpoints (RT-PCR):

- Less than 3 cycles difference: No response (NR)
- Between 3 and 6 cycles (or between 1 and 2 log): Response (R)
- Between 6 and 9 cycles (or between 2 and 3 log): Good Response (B)
- More than 9 cycles (or more than 3 log): Very Good Response (MB)

The final interpretation of the results was carried out according to the data obtained with the RT-PCR method as it better discriminates the difference in growth. The CPE and Neutral Red reading data (when used) were used to assess the evolution of the assay and to confirm the more accurate data from the RT-PCR method.

This study was conducted in accordance with the Declaration of Helsinki of 1964 and its subsequent amendments (as revised in 2013). Due to the study design, local Ethical Committee approval was not required. No personal data were handled during the study.

Experimental Results.

Description and characteristics of each assay

As mentioned above (in the methods section), three trials were carried out at different time periods.

In assay-1, the pure control results and the cells from the plate detached from the plate of 6 strains were assessed. In assay-2, 8 strains were assessed and in assay-3, 15 strains were assessed. All data from these three trials are shown in Table 1.

Of the 29 strains tested, evaluable results were obtained in 26. Overall, a response was observed in 13 (50%) pre-treated and 16 (61.5%) treated strains at inoculation ($p=0.29$). This response was good or very good in 10 (38.4%) of the pretreated and 11 (42.3%) of the treated strains ($p=0.4$).

Table 1. Experiment data; strains, titration, genomic amplification cycles (Ct) and VL (log/103 cell) in Pretreatment and Treatment.

Experiment	Strain	Titration Strain			Pretreatment with 2021-β			Treatment with 2021-β		
		CP	Neutra	PCR	CPE / (%)	PCR	Valuatio	CPE (%)	PCR	Valuatio
s	s	E	l red	Ct / VL ¹	Growth) ²	Ct/VL	n	Growth) ²	Ct / VL	n
Test 1	1	-	-	-	-	-	-	-	-	-
	2	4	-	22 / 6,7	-	22 / 7,0	NR	-	35 / 3,13	VG
	3	4	-	21 / 7,0	-	24 / 6,4	R	-	31 / 4,32	VG
	4	2	-	28 / 5,2	-	37 / 2,5	VG	-	22 / 7,0	NR

	5	2	-	21 / 6,7	-	22 / 7,0	NR	-	21 / 7,3	NR
	6	-	-	-	-	-	-	-	-	-
Test 2	1	2,5	-	25 / 6,1	-	30 / 4,6	R	-	30 / 4,6	R
	2	2,8	-	25 / 6,1	-	28 / 5,2	R	-	30 / 4,6	R
	3	2,5	-	27 / 5,5	-	40 / 1,5	VG	-	40 / 1,5	VG
	4	2,5	-	26 / 5,6	-	37 / 2,5	VG	-	37 / 2,5	VG
	5	2,1	-	26 / 5,8	-	40 / 1,5	VG	-	30 / 4,6	R
	6	2,1	-	26 / 5,8	-	40 / 1,5	VG	-	35 / 3,1	G
	7	2,8	-	27 / 5,5	-	40 / 1,5	VG	-	40 / 1,5	VG
	8	2,1	-	17 / 8,5	-	28 / 5,2	VG	-	40 / 1,5	VG
Test 3	1	3,5	4,55	29,3 / 4,83	+ / Not read	25,6 / 5,93	NR	+ / Not read	25,8 / 5,87	NR
	2	3,5	4,00	23,7 / 6,49	+ / Not read	25,6 / 5,93	NR	+ / Not read	26,5 / 5,66	R
	3	3,8	4,40	22,0 / 6,94	+ / Not read	34,6 / 3,25	VG	+ / Not read	32,1 / 3,99	VG
	4	3,5	3,20	22,6 / 6,82	+ / Not read	32,7 / 3,81	VG	+ / Not read	30,9 / 4,35	G
	5	4,8	4,00	25,4 / 5,99	+ / Not read	25,7 / 5,9	NR	+ / Not read	29,8 / 4,68	R
	6	3,5	3,10	20,8 / 7,36	+ / 100	20,9 / 7,33	NR	+ / 100	20,6 / 7,42	NR
	7	3,1	3,70	32,3 / 3,93	+ / 75	30,1 / 4,59	NR	+ / 50,50	37,9 / 2,27	VG
	8	5,8	4,60	20,3 / 7,51	+ / 100	18,6 / 8,01	NR	+ / 100	18,6 / 8,01	NR
	9	2,5	3,10	20,5 / 7,45	+ / 100	19,3 / 7,80	NR	+ / 100	29,8 / 4,68	G
	10	3,1	3,70	35,0 / 3,13	-	35,6 / 2,95	-	-	34,1 / 3,40	-
	11	3,5	4,50	24,3 / 6,31	+ / 91,40	22,8 / 6,97	NR	+ / 86,40	22,5 / 6,85	NR
	12	3,5	3,20	22,6 / 6,82	¿? / 100	32,7 / 3,81	VG	+ / 100	21,7 / 7,09	NR
	13	4,8	4,00	25,4 / 5,99	+ / 100	25,7 / 5,9	NR	+ / 100	19,5 / 7,74	NR
	14	3,5	4,00	21,7 / 7,09	+ / 85,50	21,3 / 7,21	NR	+ / 89,50	20,7 / 7,39	NR
	15	3,8	4,40	20,6 / 7,42	+ / 100	19,5 / 7,74	NR	+ / 79,30	18,5 / 8,04	NR

Ct: genomic amplification cycle, VL: viral load, NR: no response, R: normal response, G: good response, VG: very good response.

1In trials 1, 2, 4 and 5, values separated by | refer to the result of infected cultures without 2021-β for the pre-treatment (left) and treatment (right) trials.

²percentage of growth calculated with respect to uninfected cells adjacent to the dilution

Discussion

SARS-CoV-2 generates a wide range of clinical manifestations ranging from infection with mild symptoms to severe disease. Studies show that the total viral load to which the individual is exposed is relevant. Damm et al. have found that there is a dose-dependent relationship between viral load and disease severity, so it is important to assess the change in viral load over time, defined as viral

kinetics. [33] The systematic review by Billah et al. shows that assessing this parameter could provide insight into the possibility of an increase in CoV infections. [34]

The basis for this study, lies in the immune response and early evasion of the virus. In this respect, many studies have been carried out with different products tested with varying degrees of success. [35–40]

It should be emphasized that the compound under test, Potassium Ribosate, is not an antiviral, so it is necessary to interpret its ability, highlighted in some strains, to strongly reduce viral replication with a significant reduction of viral load. As mentioned in the introductory part, the working hypothesis formulated by Biochemical Research A.E.I.E., together with the Valsé Pantellini Foundation, is that the Potassium present in the compound acts on the G-quadruplexes (G4) not only of human DNA, for their formation and stabilisation, [45] but also and above all on the mRNA of the SARS-CoV-2 coronavirus.[46] Only the stabilisation of these structures by a compound or, more specifically, an element, such as the cation K^+ , which interacts with G4, can reduce viral RNA replication and inhibit protein translation.[47]

In this work, a reagent has been tested which, on the one hand, aims to improve cellular defence against alpha variants of SARS-Cov2 and, on the other hand, could act on the virus itself (although its mechanism of action is not known). Potassium Ribosate was able to alter viral replication in more than 60% of the strains. And this response was good or very good in 40% of these strains, suggesting that it is a good drug to alter viral replication and fight infection. [41–44a,b]

These results are in line with other recently tested reagents, which, although they do not reach the 80% efficiency values of direct antivirals, do present values above 60%, similar to those presented in this work. [48] To evaluate its activity, three trials were carried out, in all of which pretreatment and treatment were evaluated (as detailed in Material and Methods), in different periods due to the workload involved. And we worked with the alpha variant, which was the one available in the laboratory at the time. During the evaluation, the SARS-Cov2 typology was not modified so as not to introduce new variables that could alter the final result. The results obtained at the end of each trial for both Pretreatment and Treatment revealed viral load reductions of 50% and 61.5%; this response was Good or Very Good in 10 (38.4%) and 11 (42.3%) of the strains, respectively. In all cases that resulted in a "Very Good Response" the cytopathic effect was negative, showing the weakness of the virus to continue to affect these cultures.

In summary, administration of Potassium Ribosate reduces the viral load and cytopathic effect of SARS-CoV-2 cultured in Vero E6 cells in more than half of the cases and can be considered as a possible therapeutic/immunomodulatory method aiming to minimize viral replication in the early undetectable stages and its infectious capacity. Of course, the subject is complex, but the working hypothesis formulated may shed new light on the inhibition of viral replication using a simple and physiological molecule such as Potassium Ribosate and may open the door to further studies to better understand the mechanisms involved.

References

1. a) Hu, B., Guo, H., Zhou, P., & Shi, Z. L. (2021). Characteristics of SARS-CoV-2 and COVID-19. *Nature Reviews Microbiology*, 19(3), 141-154. b) Suhail, S., Zajac, J., Fossum, C., Lowater, H., McCracken, C., Severson, N., ... & Hati, S. (2020). Role of oxidative stress on SARS-CoV (SARS) and SARS-CoV-2 (COVID-19) infection: a review. *The protein journal*, 39, 644-656. c) Lamers, M. M., & Haagmans, B. L. (2022). SARS-CoV-2 pathogenesis. *Nature reviews microbiology*, 20(5), 270-284.
2. a) Oliveira, B. A., Oliveira, L. C. D., Sabino, E. C., & Okay, T. S. (2020). SARS-CoV-2 and the COVID-19 disease: a mini review on diagnostic methods. *Revista do Instituto de Medicina Tropical de São Paulo*, 62, e44. b) Hámilton Forero-Argüello*, A. H.-M.-B.-R. (2021). Caracterización y fisiopatología del Sars-Cov-2, Revisión de literatura actual. *Infectopatología*, 61-75. c) Cevik M., K. K. (2020). Virology, transmission, and pathogenesis of SARS-CoV-2. *BMJ*, 371:m3862.
3. Valsé Pantellini G (1970): *Breve cenno sulla genesi dei tumori e sopra una eventuale terapia dei medesimi con sali di potassio e in particolare con ascorbato di potassio*. *Rivista di Patologia e Clinica*, XXV: 219-225.

4. Valsé Pantellini G (1974): *Legami idrogeno (H) e salificazione degli stessi da parte del potassio (K) nella strutturazione della materia vivente*. **Rivista di Patologia e Clinica**, XXIX: 193-198.
5. Valsé Pantellini G (1984): *I nuovi orientamenti sulla terapia dei tumori dal punto di vista biochimico e immunologico*. In **Atti del Quarto Convegno Nazionale "L'Uomo tra Microcosmo e Macrocosmo"**. A cura di Marinucci G. Urbino: 171-176.
6. Valsé Pantellini G, Paoli G (1999): *Meccanismo d'azione dell'ascorbato di potassio nei sistemi biologici*. In **LXXXV Congresso Nazionale della Società Italiana di Fisica**, Pavia: 108.
7. Croci S, Pedrazzi G, Paoli G, Monetti D, Bronzetti G, Ortalli I (2001): *Potassium ascorbate as protective agent in oxidation of red cells*. **Anticancer Research**, 21. Abstract of the International Conference on Antioxidant in Cancer Prevention and Therapy: 1571-1572.
8. Croci S, Pedrazzi G, Paoli G, Monetti D, Ortalli I (2002): *Potassium ascorbate as protective agent in the oxidation of the red blood cells*. **Hyperfine Interactions (C)**. Proceedings of the International Conference on the Applications of the Mössbauer effect (ICAME 2001). Thomas MF, Williams JM, Gibb TC Ed.(s), Kluwer Academic Publishers: 241-244.
9. Paoli G (2003): *The biomagnetic nature of cancer and the role of potassium ascorbate and ribose against cellular degeneration*. **Journal of New Energy**, 7(3): 114-11.
10. Croci S, Bruni L, Bussolanti S, Castaldo M, Dondi M (2011): *Potassium bicarbonato and D-ribose effects on A72 canine and HTB-126 human cancer cell line proliferation in vitro*. **Cancer Cell Int**, 11:30.
11. Bruni L, Babarinde AA, Ortalli I, Croci S (2014): *K-D:rib dampens Hs 578T cancer cell chemoinvasion and proliferation*. **Cancer Cell Int**, 14:77.
12. Bruni L, Croci S (2014): *K-D:rib cancer cell proliferation inhibitor and DNAzyme folding promoter*. **Journal of Biological Research**, 87:2135.
13. Bruni L (2014): *Antitumorigenicità del D-ribosio e KHCO₃ sulla linea di carcinoma mammario Hs 578T ed effetti sulla linea d'epitelio mammario umano non tumorale Hs 578BST*. **Tesi di Dottorato di Ricerca in Biotecnologie**. Università degli Studi di Parma, Ciclo XXVI.
14. Frajese GV, Benvenuto M et al (2016): *Potassium increases the antitumor effects of ascorbic acid in breast cancer cell lines "in vitro"*. **Oncology Letters**, 11: 4224-4234.
15. Cavicchio C et al. (2017): *Potassium Ascorbate with Ribose: Promising Therapeutic Approach for Melanoma Treatment*. **Oxidative Medicine and Cellular Longevity**, Volume 2017. Article ID4256519, 12 pages. <https://doi.org/10.1155/2017/4256519>
16. Anichini C et al, (2011), *Beckwith-Wiedemann Syndrome: Potassium Ascorbate with ribose Therapy in a Syndrome with High Neoplastic Risk*. **Anticancer Research** 31: 3973-3976.
17. Anichini C et al, (2012), *Antioxidant effects of potassium ascorbate with ribose therapy in a case of Prader Willi Syndrome*. **Disease Markers** 33: 179-183
18. Anichini C et al, (2013), *Antioxidant Effects of Potassium Ascorbate with Ribose in Costello Syndrome*. **Anticancer Research** 33: 691-696
19. [Anichini C et al, \(2014\), Antioxidant strategies in genetic syndromes with high neoplastic risk in infant. Tumori 100: 590-599](#)
20. Palmer BF (2015): *Regulation of potassium homeostasis*. **Clin J Am Soc Nephrol**, 10(6): 1050-1060.
21. Gumz ML, Rabinowitz L, Wingo CS (2015): *An Integrated View of Potassium Homeostasis*. **N Engl J Med**, 373(1):60-72.
22. Palmer BF, Clegg DJ (2019): *Physiology and pathophysiology of potassium homeostasis: Core Curriculum 2019*. **Am J Kidney Dis**, 74(5): 682-695
23. Paoli G (2020): **Ascorbato di potassio. La molecola intelligente per regolare le difese dell'organismo**. Aam Terra Nuova Ed. Firenze.
24. a) Paoli G (2022): *Ribosate di potassio e SARS-CoV-2. Le connessioni inattese fra virus e molecole semplici. Natura Docet: la Natura insegna – ND, Anno III, 9:18-22.* b) Paoli G (2022): *Can a molecule be "intelligent"? Unexpected connections between Physics and Biology*. **Open Journal of Biophysics**, 12(4):234-244.
25. S.L., V. R. (2019). *STUDY PLAN B-02959 Toxicity Evaluation of the Test Item via Intramuscular Administration in Female Sprague Dawley Rats by the Acute Toxicity-Up-and-Down Procedure*. Spain: Nanoimunotech.

26. de la Iglesia, P., Melón García, S., López, B., Rodríguez, M., Blanco, M. I., Mellado, P., & de Oña, M. (1998). Rapid screening tests for determining in vitro susceptibility of herpes simplex virus clinical isolates. *Journal of clinical microbiology*, 36(8), 2389-2391.
27. Álvarez ÁL, Habtemariam S, Abdel Moneim AE, Melón S, Dalton KP, Parra F. [A spiroketal-enol ether derivative from *Tanacetum vulgare* selectively inhibits HSV-1 and HSV-2 glycoprotein accumulation in Vero cells](#). *Antiviral Res.* 2015 Jul;119:8-18. doi: 10.1016/j.antiviral.2015.04.004. Epub 2015 Apr 13.PMID: 25882624
28. Alvarez AL, Dalton KP, Nicieza I, Diñeiro Y, Picinelli A, Melón S, Roque A, Suárez B, Parra F. [Bioactivity-guided fractionation of *Phyllanthus orbicularis* and identification of the principal anti HSV-2 compounds](#). *Phytother Res.* 2012 Oct;26(10):1513-20. doi: 10.1002/ptr.4608. Epub 2012 Feb 8.PMID: 22318977
29. Pérez Martínez, Z. (2021) "Efecto de la melatonina en células infectadas con el Herpes Simplex Tipo 1". Universidad de Oviedo. Asturias-España.
30. Martín, G., Rojo-Alba, S., Castello-Abietar, C., Abreu-Salinas, F., Costales González, I., Boga, J. A., Melón, S., & Álvarez-Argüelles, M. E. (2021). Comparison of in-house SARS-CoV-2 genome extraction procedures. A need for COVID-19 pandemic. Research Square preprint doi: 10.21203/rs.3rs-214704/v1
31. Sandoval Torriente, M., Castello-Abietar, C., Boga Riveiro, J., Álvarez-Argüelles, M. E., Rojo-Alba, S., Abreu-Salinas, F., Costales González, I., Pérez Martínez, Z., Martín Rodríguez, G., Gómez de Oña, J., & Melón García, S. (2021). A novel single nucleotide polymorphism assay for the detection of N501Y SARS-CoV-2 variants. *Journal of virological methods*, 294, 114143.
32. A.E.I.E., B. R. (junio de 2021). *Biochemical Research A.E.I.E.* Obtenido de Investigación-Estudios: <https://www.aeiebiochemical.es/es/content/9-investigacion>.
33. Van Damme W., D. R. (2021). COVID-19: Does the infectious inoculum dose-response relationship contribute to understanding heterogeneity in disease severity and transmission dynamics? *Med Hypotheses*, 146.
34. Billah M.A., M. M. (2020). Reproductive number of coronavirus: A systematic review and meta-analysis based on global level evidence. *PLoS ONE*, 15(11): e0242128.
35. COVID-19 Treatment Guidelines Panel. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. National Institutes of Health. Available at: <https://www.ncbi.nlm.nih.gov/books/NBK570371/>
36. Hodgson, S. H., Mansatta, K., Mallet, G., Harris, V., Emary, K., & Pollard, A. J. (2021). What defines an efficacious COVID-19 vaccine? A review of the challenges assessing the clinical efficacy of vaccines against SARS-CoV-2. *The Lancet. Infectious diseases*, 21(2), e26-e35.
37. [Osamu Kanauchi^{1,2}](#), [Zhao Xuan Low¹](#), [Kenta Jounai²](#), [Ryohei Tsuji²](#), [Sazaly AbuBakar¹](#) Overview of anti-viral effects of probiotics via immune cells in pre-, mid- and post-SARS-CoV2 era. *Front Immunol.* 2023 Dec 5;14:1280680. doi: 10.3389/fimmu.2023.1280680. eCollection 2023.
38. [K Dhuli¹](#), [C Micheletti¹](#), [P E Maltese¹](#), [B Tanzi¹](#), [S Benedetti¹](#), [S Tezzele¹](#), [C Mareso²](#), [S T Connelly³](#), [F Gaffuri^{4,5}](#), [G M Tartaglia^{4,5}](#), [S Nodari⁶](#), [G Arabia⁷](#), [F Fioretti⁶](#), [C Calandri⁸](#), [M A Perrone⁸](#), [M Bertelli^{1,2,9}](#) The Role of Olive Tree Polyphenols In The Prevention of COVID-19: A Scoping Review Part 2 Clin Ter. 2023 Nov-Dec;174(Suppl 2(6)):149-153. doi: 10.7417/CT.2023.2481.
39. [Jorge Calderón-Parra¹](#), [Andrea Gutiérrez-Villanueva²](#), [Gerard Ronda-Roca³](#), [Maria Luisa Martín Jimenez⁴](#), [Helena de la Torre⁴](#), [María Ródenas-Baquero⁵](#), [María Paniura-Pinedo⁵](#), [Carla Lozano-Llano⁶](#), [Ilduara Pintos-Pascual⁵](#), [Ana Fernández-Cruz⁷](#), [Antonio Ramos-Martínez⁷](#), [Elena Muñoz-Rubio¹](#) Efficacy and safety of antiviral plus anti-spike monoclonal antibody combination therapy vs. monotherapy for high-risk immunocompromised patients with mild-to-moderate SARS-CoV2 infection during the Omicron era. A prospective cohort study. *Int J Antimicrob Agents.* 2024 Jan 18;63(3):107095. doi: 10.1016/j.ijantimicag.2024.107095. Online ahead of print.
40. [Saad Alhumaid¹](#), [Abbas Al Mutair^{2,3,4,5}](#), [Jalal Alali⁶](#), [Nourah Al Dossary⁷](#), [Sami Hussain Albattat⁸](#), [Sarah Mahmoud Al HajjiMohammed⁹](#), [Fatimah Saad Almuaiweed¹⁰](#), [Maryam Radhi AlZaid⁹](#), [Mohammed Jaber Alomran¹¹](#), [Zainab Sabri Alqurini¹²](#), [Ahmed Abduljalil Alsultan¹³](#), [Thamer Saeed Alhajji¹³](#), [Sukainah Mohammad Alshaikhnasir¹⁰](#), [Ali Al Motared¹⁴](#), [Koblan M Al Mutared¹⁵](#), [Khalid Hajissa¹⁶](#), [Ali A Rabaan^{17,18,19}](#) Efficacy and Safety of Tixagevimab/Cilgavimab to Prevent COVID-19 (Pre-Exposure

- Prophylaxis): A Systematic Review and Meta-Analysis Diseases 2022 Dec 1;10(4):118. doi: 10.3390/diseases10040118.
41. Marta Gargantilla, Clara Francés, Anmol Adhav, Alicia Forcada-Nadal, Belén Martínez-Gualda, Olaia Martí-Marí, María Luisa López-Redondo, Roberto Melero, Clara Marco-Marín, Nadine Gougéard, Carolina Espinosa, Antonio Rubio-del-Campo, Rafael Ruiz-Partida, María del Pilar Hernández-Sierra, Laura Villamayor-Belinchón, Jerónimo Bravo, José-Luis Llacer, Alberto Marina, Vicente Rubio, Ana San-Félix, Ron Geller, and María-Jesús Pérez-Pérez. *J. Med. Química*. 2023, 66, 15, 10432-10457.
 42. Dustin Siegel,† Hon C. Hui,† Edward Doerffler,† Michael O. Clarke,† Kwon Chun,† Lijun Zhang,† Sean Neville,† Ernest Carra,† Willard Lew,† Bruce Ross,† Queenie Wang,† Lydia Wolfe,† Robert Jordan,† Veronica Soloveva,‡ John Knox,† Jason Perry,† Michel Perron,† Kirsten M. Stray,† Ona Barauskas,† Joy Y. Feng,† Yili Xu,† Gary Lee,† Arnold L. Rheingold,§ Adrian S. Ray,† Roy Bannister,† Robert Strickley,† Swami Swaminathan,† William A. Lee,† Sina Bavari,‡ Tomas Cihlar,† Michael K. Lo,|| Travis K. Warren,‡ and Richard L. Mackman*,† *J. Med. Química*. 2017, 60, 5, 1648-1661.
 43. Beigel, J. H.; J.H. Beigel, K.M. Tomashek, L.E. Dodd, A.K. Mehta, B.S. Zingman, A.C. Kalil, E. Hohmann, H.Y. Chu, A. Luetkemeyer, S. Kline, D. Lopez de Castilla, R.W. Finberg, K. Dierberg, V. Tapson, L. Hsieh, T.F. Patterson, R. Paredes, D.A. Sweeney, W.R. Short, G. Touloumi, D.C. Lye, N. Ohmagari, M. Oh, G.M. Ruiz-Palacios, T. Benfield, G. Fätkenheuer, M.G. Kortepeter, R.L. Atmar, C.B. Creech, J. Lundgren, A.G. Babiker, S. Pett, J.D. Neaton, T.H. Burgess, T. Bonnett, M. Green, M. Makowski, A. Osinusi, S. Nayak, and H.C. Lane, for the ACTT-1 Study Group Members* *N. J. Med.* 2020, 383, 1813-1826.
 44. a) Painter, G. R.; Natchus, M. G.; Cohen, O.; Holman, W.; Painter, W. P. Developing a Direct Acting, Orally Available Antiviral Agent in a Pandemic: The Evolution of Molnupiravir as a Potential Treatment for COVID-19. *Curr. Opin. Virol.* 2021, 50, 17-22. b) Hancioglu B., S. D. (2007). A dynamical model of human immune response to influenza A virus infection. *J Theor Biol.*, 246:70-86
 45. Soldà P (2019): *Ligands-mediated modulation of G-quadruplex structures within the HIV-1 genome during lytic and latent state of infection*. **Tesi di Dottorato di Ricerca in Biomedicina**. Università degli Studi di Padova, Ciclo XXXII <https://www.research.unipd.it/retrieve/e14fb270-0211-3de1-e053-1705fe0ac030/Solda%cc%80%20Paola%20tesi.pdf>
 46. Tan J et al (2009): *The SARS-Unique Domain (SUD) of SARS Coronavirus contains two macrodomains that bind G-quadruplex*. **PLoS Pathog**, 5(5), e1000428. <http://doi.org/10.1371/journal.ppat.1000428>
 47. Brian W-X et al (2019): *Binding of cellular nucleolin with the viral core RNA G-quadruplex structure suppresses HVL replication*. **Nucleic Acids Res** 47(1):56-68 <https://doi.org/10.1093/nar/gky1177>
 48. [Abdou K Allayeh¹](#), [Aliaa H El-Boghdady²](#), [Mohamed A Said³](#), [Mahmoud G A Saleh⁴](#), [Mohammed T Abdel-Aal²](#), [Mohamed G Abouelenein²](#) Discovery of Pyrano[2,3- c]pyrazole Derivatives as Novel Potential Human Coronavirus Inhibitors: Design, Synthesis, In Silico, In Vitro, and ADME Studies. *Pharmaceuticals (Basel)*. 2024 Feb 2;17(2):198. doi: 10.3390/ph17020198.

Disclaimer/Publisher's Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.